drugset / Trial / NCT01167309
LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients
RandomizedSingle-groupDouble-blindOther
Summary
The purpose of this trial is to determine the safety and tolerability of ascending single and multiple oral doses of LEO 27847 in secondary hyperparathyroidism patients.
Timeline
- Start
- 2010-06
- Primary completion
- 2011-10
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | LEO 27847 | Unknown | 0.24 mg | Oral |